By therapeutic area: oncology readouts · rare disease readouts
This page lists 181 expected clinical trial readouts covering November 2026 to December 2027. A further 132 readouts whose window has already passed are listed below with what we found: the sponsor's release where one exists, otherwise the date we last checked. These dates come from company guidance and ClinicalTrials.gov, so most are known only to a month or a quarter, and we publish them at that precision rather than guessing a day.
These 45 dates are not trial-registry estimates. Each one is timing the company itself stated in an SEC filing, and each row links to that filing so you can read the sentence it came from. Dates are shown at the precision the company used: a quarter stays a quarter rather than being rendered as a specific day it never named. Guidance that was vaguer than a quarter is not on this page at all.
| Guided | Ticker | Program | Company | Source |
|---|---|---|---|---|
| Q4 2026 | ALNY | elebsiran | Alnylam Pharmaceuticals, Inc. | 10-K 2026-02-12 |
| Q4 2026 | ATAI | VLS-01 | AtaiBeckley Inc. | EX-99.1 2026-05-12 |
| Q4 2026 | BMEA | BMF-650 | Biomea Fusion, Inc. | EX-99.1 2026-05-11 |
| Q4 2026 | CMPX | CTX-10726 | Compass Therapeutics, Inc. | EX-99.1 2026-05-05 |
| Dec 2026 | CRIS | NCT07271667 | Curis Inc | 10-Q 2026-05-13 |
| Q4 2026 | ENTA | EDP-978 | Enanta Pharmaceuticals Inc | 424B5 2026-07-02 |
| Q4 2026 | HELP | HLP003 | Cybin Inc. | EX-99.1 2026-08-03 |
| Q4 2026 | IPSC | CNTY-813 | Century Therapeutics, Inc. | EX-99.1 2026-06-08 |
| Q4 2026 | IVEVF | lanifibranor | Inventiva S.A. | EX-99.2 2026-09-28 |
| Q4 2026 | KYNB | FG-3246 | Kyntra Bio, Inc. | 10-Q 2026-05-12 |
| Q4 2026 | LONA | ATH-1105 | LeonaBio, Inc. | EX-99.1 2026-05-07 |
| Q4 2026 | MIRM | AZURE-1 | Mirum Pharmaceuticals, Inc. | EX-99.1 2026-05-06 |
| Q4 2026 | MTVA | DA-1726 | MetaVia Inc. | EX-99.1 2026-04-10 |
| Q4 2026 | PCVX | OPUS-1 | Vaxcyte, Inc. | EX-99.1 2026-05-06 |
| Q4 2026 | RAPP | RAP-219 | Rapport Therapeutics, Inc. | EX-99.1 2026-05-07 |
| Q4 2026 | RGNX | RGX-314 | REGENXBIO Inc. | EX-99.1 2026-06-29 |
| Q4 2026 | SKYE | nimacimab | Skye Bioscience, Inc. | 10-Q 2026-05-11 |
| Q4 2026 | SLGL | SGT-610 | Sol-Gel Technologies Ltd. | EX-99.1 2026-05-28 |
| Q4 2026 | SLS | SLS009 | SELLAS Life Sciences Group, Inc. | EX-99.1 2026-05-12 |
| Q4 2026 | SLS | galinpepimut-S (GPS) event-driven | SELLAS Life Sciences Group, Inc. | EX-99.1 2026-05-12 |
| Q4 2026 | SNDX | SNDX-62122 | Syndax Pharmaceuticals Inc | EX-99.1 2026-07-14 |
| Q4 2026 | TRAX | ANB033 | First Tracks Biotherapeutics, Inc. | EX-99.1 2026-05-14 |
| Q4 2026 | ZBIO | ZB021 | Zenas BioPharma, Inc. | EX-99.1 2026-05-13 |
| Q1 2027 | AKTS | AKY-1189 | Aktis Oncology, Inc. | EX-99.1 2026-05-11 |
| Q1 2027 | CRBP | CRB-701 | Corbus Pharmaceuticals Holdings, Inc. | 10-Q 2026-05-12 |
| Q1 2027 | DYN | z-basivarsen (DYNE-101) | Dyne Therapeutics, Inc. | 8-K 2026-09-29 |
| Q1 2027 | MBRX | Annamycin | Moleculin Biotech, Inc. | EX-99.1 2026-09-29 |
| Q1 2027 | NMRA | NMRA-511 | Neumora Therapeutics, Inc. | EX-99.1 2026-05-07 |
| Q1 2027 | OCUL | HELIOS-3 | Ocular Therapeutix, Inc | 10-Q 2026-05-05 |
| Q1 2027 | QNCX | LAM-001 | Quince Therapeutics, Inc. | EX-99.4 2026-07-30 |
| Q1 2027 | TTRX | GX-03 | Turn Therapeutics Inc. | EX-99.1 2026-10-07 |
| Q2 2027 | IRD | OPGx-BEST1 (AAV gene therapy) | Opus Genetics, Inc. | EX-99.1 2026-09-09 |
| Q2 2027 | PROK | REGEN-006 | Prokidney Corp. | EX-99.2 2026-05-15 |
| 2027-12-31 | ANL | AN4035 (CEACAM5 ADC) | Adlai Nortye Group Ltd. | EX-99.1 2026-09-08 |
| 2027-12-31 | BIOA | BGE-102 (oral NLRP3 inhibitor) | BioAge Labs, Inc. | 8-K 2026-10-02 |
| Q4 2027 | EYPT | DURAVYU | EyePoint, Inc. | EX-99.1 2026-08-17 |
| 2027-12-31 | GPCR | ACCG-2671 (oral amylin agonist) | Structure Therapeutics Inc. | EX-99.1 2026-09-08 |
| Q4 2027 | IMA | olevaprubart (IMG-007) | ImageneBio, Inc. | EX-99.1 2026-08-05 |
| Q4 2027 | KLRS | TH103 | Kalaris Therapeutics, Inc. | EX-99.2 2026-07-17 |
| 2027-12-31 | KRRO | KRRO-121 (RNA-editing oligo) | Korro Bio, Inc. | EX-99.1 2026-10-05 |
| 2027-12-31 | KZIA | paxalisib | KAZIA THERAPEUTICS LTD | EX-99.2 2026-08-31 |
| Q4 2027 | LSTA | MAR002 | LISATA THERAPEUTICS, INC. | EX-99.2 2026-09-17 |
| 2027-12-31 | PCVX | VAX-31 | Vaxcyte, Inc. | EX-99.2 2026-10-05 |
| 2027-12-31 | TRXB | TRB-061 (TNFR2 agonist) | TRex Bio, Inc. | S-1 2026-09-18 |
| 2027-12-31 | TYRA | SURF303 | Tyra Biosciences, Inc. | EX-99.1 2026-05-13 |
209 expected readouts are on the calendar as of November 5, 2026, each with its company-guided window and source.
No. We publish dates, trial designs and measured stock reactions, each linked to its source; we do not publish outcome predictions or approval probabilities.
The date a clinical trial's results become public, usually announced by the sponsor; unlike a PDUFA date it is an estimate until the company fixes it.